GLP-2

PreclinicalSmall molecule

GGlostrup University Hospital, Copenhagen

GLP-2 is one of 19 small molecule programs targeting Short Bowel Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Short Bowel SyndromeActive, not recruiting

HumansUnknown status

Short Bowel SyndromePreclinical

Active, not recruiting

HumansPreclinical

Unknown status

Competition

Competitive Landscape

13 competitors in Short Bowel Syndrome

#DrugCompanyPhaseTrials

Eliquis

Bristol-Myers Squibb

Approved

1 2

Victoza

Glepaglutide

5 4

Apraglutide

VVectivBio AG

Phase 3

2 5

PJ009

CChongqing Peg-Bio Biopharm Co., Ltd.

Phase 3

1 6

Celexa

AbbVie

Preclinical

1 7

Mytesi

NNapo Pharmaceuticals, Inc.

Phase 1

1 8

Glutamine

Sanofi

Preclinical

1 9

Genotropin

EMD Serono

Preclinical

—10

FT1

CChongqing Peg-Bio Biopharm Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Function

NCT06194955

Clinical

Trials by Indication[1]

Humans1 trial

The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

Unknown status·GGlostrup University Hospital, Copenhagen·N/A·NCT00273000·10 enrolled

Acute Lymphoblastic Leukemia1 trial

Effect of Glucagon-like Peptide 2 on Gallbladder Motility After a Meal in Young, Healthy Male Subjects

Completed·SSteno Diabetes Center Copenhagen·Phase 1·NCT03682172·15 enrolled

Function1 trial

The Effect of GIP, GLP-1 and GLP-2 in Individuals With Genetically Altered Receptor Function

Recruiting·UUniversity of Copenhagen·N/A·NCT06194955·60 enrolled

Short Bowel Syndrome1 trial

Effect of the Enteric Hormone Glucagon-Like Peptide (GLP-2) on the Intestinal Blood Flow in Patients With Short Bowel Syndrome

Unknown status·GGlostrup University Hospital, Copenhagen·N/A·NCT00673751·8 enrolled

Lip1 trial

Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Like Peptide 2

Completed·UUniversity Health Network, Toronto·Phase 3·NCT01958775·12 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GLP-2. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GLP-2 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GLP-2. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Glostrup University Hospital, Copenhagen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: GGlostrup University Hospital, Copenhagen

GLP-2

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Humans1 trial

Acute Lymphoblastic Leukemia1 trial

Function1 trial

Short Bowel Syndrome1 trial

Lip1 trial

References

Drug Info

Quick Facts

Related News